<DOC>
	<DOCNO>NCT01930045</DOCNO>
	<brief_summary>This study evaluate effect single dos magnesium/aluminum antacid ( MAALOX ) give 4 6 hour administration raltegravir , pharmacokinetics raltegravir human immunodeficiency virus ( HIV ) -infected participant . The study consist Part 1 ( Periods 1 , 2 , 3 ) Part 2 ( Periods 4 5 ) , study period separate washout period least 2 day ; Part 1 separate Part 2 Pause . Each study period duration ≥2 day , pause evaluation Part 1 pharmacokinetics result continue Part 2 . The participant participate Parts 1 2 . The primary hypothesis test ( Part 1 ) raltegravir plasma concentration 12 hour administration ( C 12 hr ) would differ significantly raltegravir C 12 hr antacid administer 4 hour 4 hour raltegravir .</brief_summary>
	<brief_title>A Pharmacokinetic Study Evaluate Effect MAALOX Raltegravir ( MK-0518 ) Human Immunodeficiency Virus ( HIV ) -Infected Participants ( MK-0518-295 )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Aluminum hydroxide , magnesium hydroxide , drug combination</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>On stable raltegravir dose part stable antiretroviral regimen ≥1 month study If female , pregnant breast feed Body mass index ≤32 kg/m^2 Mentally physically incapacitate , significant emotional problem , history clinically significant psychiatric disorder within ≤10 year History clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary , major neurological abnormality disease ( exclude HIV ) History gastric bypass surgery History cancer , except adequately treat nonmelanomatous skin carcinoma carcinoma situ cervix malignancy successfully treat ≥10 year study History chronic diarrhea within ≤3 month study History significant multiple and/or severe allergy ( food , drug , latex ) , anaphylactic reaction significant intolerability drug food Had major surgery donate lose ≥1 unit blood ( 500 mL ) ≤4 week study Participated another investigational trial ≤4 week study Taking rifampin unable refrain use 1 ) proton pump inhibitor 2 week throughout study , 2 ) histamine H2blockers , antacid , calcium supplement , multivitamins 2 week throughout study Consumes &gt; 3 glass alcoholic beverage per day Consumes excessive amount caffeine beverage ( coffee , tea , cola , energy drink , caffeinated drink ) per day Currently use history drug abuse within ≤6 month study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>